Marinus Pharmaceuticals, Inc.

Greetings and welcome to the Marinus Pharmaceuticals first quarter 2022 financial results and business update call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. If you would like to remove yourself, please press star 1 again. And now it is my pleasure to introduce your host, Sasha Damouni-Ellis, Vice President of Corporate Affairs and Investor Relations.

You may begin. Thank you, and good afternoon, everyone.

With me from Marinus are Dr. Scott Bronstein, Chief Executive Officer, Dr. Joe Houlihan, Chief Medical Officer, and Steve Sandsfield, Chief Financial Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q, and 8-K. I will now turn the call over to our CEO, Scott Bronstein.